Columbia researchers capture the first 3D structure of the parasite's 'moving junction,' a ring of proteins that physically remodels red blood cells during invasion, and use it to design a synthetic protein that blocks infection in the lab.
For half a century, textbooks described the moment a malaria parasite forces its way into a red blood cell as something almost architectural: a ring of proteins called the moving junction formed at the entry point, the parasite slid through, and the door closed behind it. New work from Columbia University has overturned that picture. The moving junction is not a doorway. It is a molecular machine, and for the first time, researchers can see exactly how it works.
The window in which that machine operates is brutally short. According to multiple accounts of the research, the moving junction assembles, does its work, and falls apart in roughly 60 seconds, which is why no one has ever caught it in high resolution before. To get around that, the team used cryo-electron tomography, which images flash-frozen cells in three dimensions, on parasites frozen at the instant of invasion, then computationally extracted the intact junction from inside the red blood cell. The result, reported by Genetic Engineering & Biotechnology News, is the first high-resolution 3D structure of the moving junction during active invasion.
What the structure shows is a radical departure from the textbook view. The moving junction is not a passive ring the parasite slips through; it is an active complex that physically pulls and reshapes the host erythrocyte membrane, hauling the parasite inside. As News-Medical frames it, the new picture overturns long-standing assumptions about how the parasite enters human cells. The structural and functional groundwork for this image sits in two earlier references: a 2023 Nature Communications cryo-tomography framework that built the imaging pipeline for apicomplexan parasites, and earlier work in PLOS Pathogens that first characterized the junction's protein components.
Once the structure was in hand, the team turned the result into a different kind of story. They used the resolved complex as a blueprint to computationally design a mini-protein from scratch, a de novo molecule that does not exist in nature and was never seen in a parasite. In laboratory tests, that designed protein blocks invasion. It is a proof of concept, not a drug candidate. There is no clinical timeline, no dosing, no tested molecule in animals. What it shows is that once the moving junction can be seen in atomic detail, molecules can be designed to jam it.
The broader stakes sit outside the structural biology. Malaria still kills roughly 600,000 people a year, most of them young children in sub-Saharan Africa, and the parasite is steadily losing susceptibility to frontline artemisinin-based drugs in Southeast Asia and, more recently, in parts of Africa. A mechanism no one could see clearly could not be rationally targeted. Now it can. The Columbia team's framing, echoed by Mirage News, describes the work as a foundation for an entirely new class of antimalarials aimed at the invasion step itself.
Several caveats belong in the same breath. The mechanism reversal and the de novo inhibitor are a single group's result. No independent third-party validation of the structural or design claims appears in the available reporting, and the primary publication venue, exact paper title, DOI, and full author list still need confirmation beyond the press materials. Whether designed mini-proteins can be made stable, deliverable, and effective inside a living human is a question the field has barely begun to ask. What the work does establish is harder to walk back. After fifty years of speculation, scientists can now watch the parasite's doorway open and close, and they have shown they can build a key that fits the lock.